Qalsody-Tofersen
Qalsody is the first FDA‑approved antisense oligonucleotide treatment for amyotrophic lateral sclerosis (ALS) associated with SOD1 gene mutations. It reduces SOD1 protein synthesis by targeting SOD1 mRNA, addressing disease progression at a genetic level.
Miebo-Perfluorhexyloctane
Miebo is an eye drop that treats dry eye disease by reducing tear evaporation. It forms a protective layer on the eye to keep it moist and comfortable.
Elfabrio-Pegunigalsidase Alfa-Iwxj
Elfabrio is the first PEGylated enzyme replacement therapy approved by the FDA for adults with Fabry disease. It provides exogenous alpha‑galactosidase A to reduce globotriaosylceramide accumulation and improve organ function.
Veozah-Fezolinetant
Veozah is the first FDA‑approved non‑hormonal oral neurokinin 3 (NK3) receptor antagonist for moderate to severe vasomotor symptoms (hot flashes and night sweats) due to menopause. It blocks neurokinin B activity in the hypothalamus to regulate body temperature without estrogen .
Epkinly-Epcoritamab-Bysp
Epkinly is an injection used for certain types of blood cancer like large B-cell lymphoma. It helps immune cells find and destroy cancer cells.
Xacduro-Sulbactam And Durlobactam
Xacduro is an IV antibiotic used for serious lung infections caused by resistant Acinetobacter bacteria. It combines two medicines to fight tough infections effectively.
Paxlovid-Nirmatrelvir And Ritonavir
Paxlovid is an oral treatment for mild to moderate COVID-19 in high-risk patients. It stops the virus from multiplying and helps prevent severe illness when taken early.
Posluma-Flotufolastat F 18
Posluma is a PSMA-targeted PET imaging agent used in prostate cancer. It helps doctors detect and locate primary and metastatic prostate tumors more accurately using a novel radiohybrid compound.
Inpefa-Sotagliflozin
Inpefa is a once-daily oral tablet for adults with heart failure, with or without type 2 diabetes or kidney disease. It reduces the risk of cardiovascular death, hospitalization, or urgent heart failure visits.
Leqembi-Lecanemab-Irmb
Leqembi is a prescription medicine for early-stage Alzheimer’s disease. It’s a monoclonal antibody that helps reduce amyloid plaques in the brain and is the first treatment of its kind approved in the European Union.
